A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Saysnews2024-04-04T12:18:29+00:00April 4th, 2024|The New York Times|
An Ozempic Relative Slowed Parkinson’s Disease in a Small Studynews2024-04-03T21:02:24+00:00April 3rd, 2024|The New York Times|
Lo que hay que saber sobre la ibogaínanews2024-03-09T10:02:51+00:00March 9th, 2024|The New York Times|
A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Marketnews2024-03-08T15:06:16+00:00March 8th, 2024|The New York Times|
Powerful Psychedelic Drug Gains New Notice as an Opioid Addiction Therapynews2024-03-05T18:32:51+00:00March 5th, 2024|The New York Times|
What to Know About Ibogaine, a Psychedelicnews2024-03-05T08:00:07+00:00March 5th, 2024|The New York Times|
R.S.V. Vaccines May Slightly Increase Risk of Rare Neurological Conditionnews2024-02-29T22:20:23+00:00February 29th, 2024|The New York Times|
What to Know About Xolair and Food Allergiesnews2024-02-25T18:54:05+00:00February 25th, 2024|The New York Times|
Drug Drastically Reduces Children’s Reactions to Traces of Food Allergensnews2024-02-25T18:45:08+00:00February 25th, 2024|The New York Times|
Gene Therapies Could Transform Rare Diseases. Are We Holding Them Back?news2024-02-19T22:47:36+00:00February 19th, 2024|The New York Times|
